About this data
What it is
When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
Who files it
The insider, usually through the company, within two business days of the trade.
How current
We collect new filings throughout the day on SEC business days.
Worth knowing
Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.

All of this comes from public filings.

Open-market trades per day, last 30 days

05001,000Oct 17 · Purchases: 0Oct 17 · Sales: 0Oct 17Oct 18 · Purchases: 0Oct 18 · Sales: 0Oct 19 · Purchases: 29Oct 19 · Sales: 159Oct 20 · Purchases: 45Oct 20 · Sales: 209Oct 21 · Purchases: 38Oct 21 · Sales: 183Oct 21Oct 22 · Purchases: 50Oct 22 · Sales: 130Oct 23 · Purchases: 77Oct 23 · Sales: 126Oct 24 · Purchases: 1Oct 24 · Sales: 0Oct 25 · Purchases: 0Oct 25 · Sales: 0Oct 25Oct 26 · Purchases: 60Oct 26 · Sales: 171Oct 27 · Purchases: 27Oct 27 · Sales: 217Oct 28 · Purchases: 44Oct 28 · Sales: 135Oct 29 · Purchases: 35Oct 29 · Sales: 199Oct 29Oct 30 · Purchases: 68Oct 30 · Sales: 270Oct 31 · Purchases: 3Oct 31 · Sales: 0Nov 1 · Purchases: 2Nov 1 · Sales: 0Nov 2 · Purchases: 79Nov 2 · Sales: 826Nov 2Nov 3 · Purchases: 66Nov 3 · Sales: 337Nov 4 · Purchases: 67Nov 4 · Sales: 535Nov 5 · Purchases: 108Nov 5 · Sales: 458Nov 6 · Purchases: 137Nov 6 · Sales: 390Nov 6Nov 7 · Purchases: 0Nov 7 · Sales: 0Nov 8 · Purchases: 0Nov 8 · Sales: 0Nov 9 · Purchases: 110Nov 9 · Sales: 457Nov 10 · Purchases: 97Nov 10 · Sales: 406Nov 10Nov 11 · Purchases: 98Nov 11 · Sales: 330Nov 12 · Purchases: 54Nov 12 · Sales: 167Nov 13 · Purchases: 23Nov 13 · Sales: 28Nov 14 · Purchases: 0Nov 14 · Sales: 0Nov 14Nov 15 · Purchases: 0Nov 15 · Sales: 0
05001,000Oct 17 · Purchases: 0Oct 17 · Sales: 0Oct 17Oct 18 · Purchases: 0Oct 18 · Sales: 0Oct 19 · Purchases: 29Oct 19 · Sales: 159Oct 20 · Purchases: 45Oct 20 · Sales: 209Oct 21 · Purchases: 38Oct 21 · Sales: 183Oct 21Oct 22 · Purchases: 50Oct 22 · Sales: 130Oct 23 · Purchases: 77Oct 23 · Sales: 126Oct 24 · Purchases: 1Oct 24 · Sales: 0Oct 25 · Purchases: 0Oct 25 · Sales: 0Oct 25Oct 26 · Purchases: 60Oct 26 · Sales: 171Oct 27 · Purchases: 27Oct 27 · Sales: 217Oct 28 · Purchases: 44Oct 28 · Sales: 135Oct 29 · Purchases: 35Oct 29 · Sales: 199Oct 29Oct 30 · Purchases: 68Oct 30 · Sales: 270Oct 31 · Purchases: 3Oct 31 · Sales: 0Nov 1 · Purchases: 2Nov 1 · Sales: 0Nov 2 · Purchases: 79Nov 2 · Sales: 826Nov 2Nov 3 · Purchases: 66Nov 3 · Sales: 337Nov 4 · Purchases: 67Nov 4 · Sales: 535Nov 5 · Purchases: 108Nov 5 · Sales: 458Nov 6 · Purchases: 137Nov 6 · Sales: 390Nov 6Nov 7 · Purchases: 0Nov 7 · Sales: 0Nov 8 · Purchases: 0Nov 8 · Sales: 0Nov 9 · Purchases: 110Nov 9 · Sales: 457Nov 10 · Purchases: 97Nov 10 · Sales: 406Nov 10Nov 11 · Purchases: 98Nov 11 · Sales: 330Nov 12 · Purchases: 54Nov 12 · Sales: 167Nov 13 · Purchases: 23Nov 13 · Sales: 28Nov 14 · Purchases: 0Nov 14 · Sales: 0Nov 14Nov 15 · Purchases: 0Nov 15 · Sales: 0

Purchases Sales

By trade date. Insiders have two business days to file, so the most recent days fill in later.

Latest open-market insider trades

Reset

Showing: ticker NKTR

Latest open-market insider trades
TradedInsiderCompanyTypeSharesPriceValueFiling
Aug 18, 2026Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale186$71.98$13.4K SaleForm 4 ↗
Aug 18, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale418$71.98$30.1K SaleForm 4 ↗
Jun 30, 2026Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale5,681$70.00$397.7K SaleForm 4 ↗
Jun 17, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale4,500$61.65$277.4K SaleForm 4 ↗
Jun 17, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale5,500$60.81$334.5K SaleForm 4 ↗
Jun 16, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale4,697$60.71$285.2K SaleForm 4 ↗
Jun 16, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale5,303$59.97$318.0K SaleForm 4 ↗
Jun 15, 2026Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale5,538$60.71$336.2K SaleForm 4 ↗
May 19, 2026Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale199$65.51$13.0K SaleForm 4 ↗
May 19, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale444$65.51$29.1K SaleForm 4 ↗
Feb 18, 2026Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale180$73.00$13.1K SaleForm 4 ↗
Feb 18, 2026Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale423$73.00$30.9K SaleForm 4 ↗
Jan 20, 2026Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale3,867$35.67$137.9K SaleForm 4 ↗
Nov 25, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale1,157$54.28$62.8K SaleForm 4 ↗
Nov 25, 2025Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale630$54.28$34.2K SaleForm 4 ↗
Nov 25, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale2,207$54.28$119.8K SaleForm 4 ↗
Sep 9, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,210$48.18$58.3K SaleForm 4 ↗
Sep 9, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale2,156$47.49$102.4K SaleForm 4 ↗
Sep 9, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,200$46.41$55.7K SaleForm 4 ↗
Sep 9, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale2,100$45.16$94.8K SaleForm 4 ↗
Sep 5, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,136$39.89$45.3K SaleForm 4 ↗
Sep 5, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale2,226$38.82$86.4K SaleForm 4 ↗
Sep 5, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale3,304$37.87$125.1K SaleForm 4 ↗
Sep 4, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale307$35.69$11.0K SaleForm 4 ↗
Sep 4, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale189$34.41$6,503 SaleForm 4 ↗
Sep 4, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale432$33.60$14.5K SaleForm 4 ↗
Sep 4, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale793$32.43$25.7K SaleForm 4 ↗
Sep 4, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,134$35.80$40.6K SaleForm 4 ↗
Sep 4, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale613$34.40$21.1K SaleForm 4 ↗
Sep 4, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,496$33.54$50.2K SaleForm 4 ↗
Sep 4, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,923$32.37$62.2K SaleForm 4 ↗
Sep 2, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale485$30.10$14.6K SaleForm 4 ↗
Sep 2, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,500$30.16$45.2K SaleForm 4 ↗
Aug 19, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale725$26.59$19.3K SaleForm 4 ↗
Aug 19, 2025Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale676$26.59$18.0K SaleForm 4 ↗
Aug 19, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale1,573$26.59$41.8K SaleForm 4 ↗
May 19, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale10,712$0.67$7,177 SaleForm 4 ↗
May 19, 2025Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale9,996$0.67$6,697 SaleForm 4 ↗
May 19, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale23,208$0.67$15.5K SaleForm 4 ↗
Feb 19, 2025Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale10,300$1.01$10.4K SaleForm 4 ↗
Feb 19, 2025Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale11,040$1.01$11.2K SaleForm 4 ↗
Feb 19, 2025Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale23,774$1.01$24.0K SaleForm 4 ↗
Dec 24, 2024Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale16,560$0.89$14.7K SaleForm 4 ↗
Dec 23, 2024Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale33,402$0.90$30.1K SaleForm 4 ↗
Dec 19, 2024Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale51,115$0.94$48.0K SaleForm 4 ↗
Dec 18, 2024Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale85,035$0.99$84.2K SaleForm 4 ↗
Dec 17, 2024Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale46,995$1.01$47.5K SaleForm 4 ↗
Nov 19, 2024Jonathan Zalevsky
Chief R&D Officer
NKTR
Nektar Therapeutics
Sale7,785$1.01$7,863 SaleForm 4 ↗
Nov 19, 2024Mark Andrew Wilson
Chief Legal Officer
NKTR
Nektar Therapeutics
Sale6,407$1.01$6,471 SaleForm 4 ↗
Nov 19, 2024Howard W. Robin
President & CEO, Director
NKTR
Nektar Therapeutics
Sale16,278$1.01$16.4K SaleForm 4 ↗

50 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:00 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances